SCIENTIFIC REPORTS

OPEN

P2×7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M₂ receptors: autoantibody levels, heart functionality and cytokine expression

Received: 26 August 2015
Accepted: 22 October 2015
Published: 23 November 2015

Camila Guerra Martinez^{1,4}, Daniel Zamith-Miranda², Marcia Gracindo da Silva^{1,4}, Karla Consort Ribeiro⁵, Izaira Trincani Brandão³, Celio Lopes Silva³, Bruno Lourenço Diaz¹, Maria Bellio², Pedro Muanis Persechini^{1,4} & Eleonora Kurtenbach^{1,4}

Autoantibodies against the M₂ receptors (M₂AChR) have been associated with Dilated Cardiomyopathy (DCM). In the heart, P2×7 receptors influence electrical conduction, coronary circulation and response to ischemia. They can also trigger pro-inflammatory responses and the development of neurological, cardiac and renal disorders. Here, P2×7^{-/-} mice displayed an increased heart rate and ST segment depression, but similar exercise performance when compared to wild type (WT) animals. After immunization with plasmid containing M₂AChR cDNA sequence, WT mice produced anti-M₂AChR antibodies, while P2×7^{-/-} mice showed an attenuated production. Despite this, WT and P2×7^{-/-} showed left ventricle cavity enlargement and decreased exercise tolerance. Transfer of serum from M₂AChR WT immunized mice to naïve recipients led to an alteration in heart shape. P2×7^{-/-} mice displayed a significant increase in the frequency of spleen regulatory T cells population, which is mainly composed by the FoxP3⁺CD25⁺ subset. M₂AChR WT immunized mice showed an increase in IL-1β, IFNγ and IL-17 levels in the heart, while P2×7^{-/-} group produced lower amounts of IL-1β and IL-17 and higher amounts of IFNγ. These results pointed to previously unnoticed roles of P2×7 in cardiovascular and immune systems, and underscored the participation of IL-17 and IFNγ in the progress of autoimmune DCM.

Dilated cardiomyopathy (DCM) is the most common form of heart muscle disease, accounting for 60% of cardiomyopathies. It is primarily characterized by an enlargement of the heart cavities, particularly the left ventricle. Systolic contractile dysfunction and a reduction of up to 50% in the ejection fraction

¹Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brasil. ²Instituto de Microbiologia Prof. Paulo de Góes, Universidade Federal do Rio de Janeiro, 21941-900 Rio de Janeiro, RJ, Brasil. ³Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP, Brasil. ⁴Instituto Nacional de Ciência e Tecnologia para Pesquisa Translacional em Saúde e Ambiente na Região Amazônica, Conselho Nacional de Desenvolvimento Científico e Tecnológico/MCT, Rio de Janeiro, Brasil. ⁵Instituto Nacional de Propriedade Industrial. Rua São Bento no 1, Rio de Janeiro, RJ, 20090-010, Brazil. Correspondence and requests for materials should be addressed to E.K. (email: kurten@biof.ufrj.br)

are also observed. DCM can be the final outcome of several diseases and/or injuries, including ischemia, hypertension, alcohol toxicity, previous viral and non-viral infections, genetic abnormalities and autoimmune disorders^{1,2}.

In the 90's, several authors described that patients with DCM presented antibodies against muscarinic acetylcholine receptor subtype M_2 (M_2AChR), with the second extracellular loop ($M_2AChR-el_2$) the most characterized epitope³. These antibodies reproduce the negative chronotropic effect of muscarinic agonists in isolated heart, an effect inhibited by the muscarinic antagonist atropine^{4,5}. Antibodies against $M_2AChR-el_2$ induced a higher decrease in the heart rate of mice treated with carbachol, indicating that anti- M_2AChR antibodies lead to a reduction of parasympathetic tone⁶. In addition, a study with 104 DCM patients demonstrated that those positive for anti- M_2AChR (40%) displayed a higher incidence of atrial fibrillation when compared with anti- M_2AChR -negative patients⁷.

Besides auto-antibodies, several other immune mechanisms are important in the pathophysiology of the mammalian heart⁸. A series of experiments have established the involvement of $IFN\gamma$ and IL-17 in autoimmune disorders and their severity^{9,10}. These cytokines are produced mainly by Th1 and Th17 cells, respectively¹¹, although in some instances it is also possible to observe a shift from Th17 cells to a Th1 phenotype, where Th17 cells can synthesize $IFN\gamma$ ^{12,13}. The role of these two cytokines has been extensively studied in DCM models^{14–16} and their importance seems to be dependent on the study model used¹¹.

In experimental autoimmune myocarditis model (EAM) using myocardiogenic peptide derived from alpha-cardiac myosin heavy chain accompanied for 62 days, $IFN\gamma$ presented a protective role. This finding was well reported by using *Ifng*^{-/-} mice that showed an increased in heart dilatation and Left Ventricle (LV) mass increment around the 23th day^{15–17}. In an opposite way, using IL17 deficient mice, these authors showed that this cytokine played a harmful role especially promoting heart remodeling, fibrosis and dilatation^{15–17}.

Indeed, in the cases where the progression of DCM takes a longer time, such as in animals or patients with Chagas' disease that has evolved into the cardiac form, $IFN\gamma$ has been classically characterized as a key injurious element^{18,19}. Also, it has been shown recently that the amount of IL-17 is an important factor in this situation^{20,21}. Chagas' patients showing ejection fraction around 35% had lower levels of CD3⁺CD4⁺IL17⁺ cells and higher $IFN\gamma$ compared with those with preserved global left ventricular function (higher than 50%). In overall, these results suggest that the balance of these two cytokines may influence the evolution of dilated cardiac pathogenesis.

Our group established a model where mice immunized with the pcDNA3-h M_2 , a DNA plasmid carrying the entire M_2AChR cDNA sequence, developed anti- M_2AChR -associated DCM that mimicked important characteristics of human DCM, such as a decrease in LV wall thickness and a reduction in fractional shortening (FS)²². Also, the histopathological analysis of their hearts revealed disarray in the organization of myofibrils and the presence of areas of fibrosis. Thus, this plasmid-based model opened new possibilities to a better understanding of immune- and non-immune mechanisms underlying the development of DCM.

Particularly, P2 $\times$ 7 receptors are important modulators of the immune response which participate in the activation of NALP3 inflammasome. This inflammasome assembly requires the presence of danger molecules such as urate crystals, viral RNA/DNA and the bacterial-derived lipopolysaccharide LPS and extracellular ATP stimulus resulting in a reduction of intracellular K⁺ concentrations²³. As consequence the caspase 1 activation and the processing and release of mature IL-1 β and IL-18 by macrophages and other cell types occur, triggering pro-inflammatory immune responses and pyroptotic cell death^{23–25}.

Besides to be involved in antigen processing, regulatory T (Treg) cell function, leukocyte migration, and in the interaction between the innate and acquired immune systems^{26–28} the participation of P2 $\times$ 7 in cardiac system was recently described. The treatment of rodents with P2 $\times$ 7 antagonists improved heart functional parameters in injury/reperfusion and experimental autoimmune myocarditis models^{29–32}, although it has also been described that exposure to extracellular ATP at preconditioning or postconditioning periods can act as cardioprotectant in acute myocardial infarction³¹.

Due to the importance of P2 $\times$ 7 receptors to both the cardio-vascular and immune systems, we hypothesized that they may be important players in the cascade of events that connects the administration of pcDNA3-h M_2 DNA plasmids, the production of auto-antibodies, cytokine production, Treg cell numbers, and the development of autoimmune DCM. In the present study, C57BL/6/J, WT and P2 $\times$ 7^{-/-} mice were immunized with the pcDNA3-h M_2 DNA plasmid and immunological and cardiac parameters were followed over 40 weeks post-immunization. The results allowed us to gain new insights into the role of the immune system and P2 $\times$ 7 receptors in the development of DCM, and to uncover the important role played by P2 $\times$ 7 receptors in the heart's electrical function and in the chain of events that leads to the production of antibodies after plasmidial immunization.

Results

Anti- M_2AChR serum antibody production in immunized mice. A synthetic peptide corresponding to $M_2AChR-el_2$ was used to detect the anti- M_2AChR antibody production in animals immunized with the plasmid encoding the full sequence of M_2AChR (pcDNA3-h M_2). M_2AChR wild type (WT – full black lines) mice produced higher levels of anti- M_2AChR antibodies from the 5th week post-immunization as compared to the control animals immunized with the empty pcDNA3 plasmid (Fig. 1 – full grey

Figure 1. Anti-M₂AChR antibodies production in immunized animals. The dosages of anti-M₂AChR-eI₂ IgG antibodies produced by pcDNA3 controls (grey symbols) and pcDNA3-hM₂ (black symbols) immunized mice were performed by ELISA. WT animals are represented by full lines and P2×7^{-/-} animals are represented by dashed lines. The values were expressed as the optic density at 450 nm. All analyses were performed in pools of serum from 10 animals. The arrows indicate time of immunization. The data points are presented as the means ± S.E.M from three independent experiments.

Figure 2. Ergometry. Mice were subjected to exercise tests on a treadmill before and 40th week after plasmid immunization. The pre-immunization mice (eight weeks old) are represented by grey bars (N = 10). Non-immunized mice (N = 5, dashed bars) with the same age as immunized mice (57 weeks old) were submitted to the same test. Mice immunized with pcDNA3-hM₂ are represented by black bars (N = 5) and with pcDNA3 plasmid by white bars (N = 5). The letter **a** indicates a comparison between the WT pcDNA3 and WT M₂AChR groups, while letter **b** indicates a comparison between the P2×7^{-/-} pcDNA3 and P2×7^{-/-} M₂AChR groups. In these cases $p < 0.05$ was considered statistically significant. **($p < 0.01$) and ***($p < 0.001$) indicate comparison of the results obtained for immunized mice groups at 40 weeks with those obtained at the pre-test (grey bar).

lines). The levels of IgG against the muscarinic receptor peaked at the 12th week post-immunization and were maintained throughout the experimental protocol, with a tendency to decrease after the 28th week post-immunization.

In contrast, P2×7^{-/-} mice immunized with the same plasmids (Fig. 1 – dashed black lines) presented a different antibody profile, with initially lower levels of anti-M₂AChR antibodies that increased only at the 28th week post-immunization, four weeks after the second set of immunizations. Control P2×7^{-/-} animals immunized with the empty pcDNA3 plasmid (Fig. 1 – dashed grey lines) did not produce significant amounts of anti-M₂AChR antibodies.

Ergometry. Next, we performed functional and heart morphological analyses to investigate comparatively the establishment of DCM in WT and P2×7^{-/-} mice.

Using the treadmill stress test, the exercise times and maximum speeds achieved were evaluated before immunization (corresponding to animal age of eight weeks) and 40 weeks after immunization (corresponding to 57-week old) (Fig. 2). At the 40th week post-immunization, a decrease in the exercise time was observed in WT and P2×7^{-/-} mice either immunized with pcDNA3 (Fig. 2 – white bars) or M₂AChR (Fig. 2 – black bars) and also in non-immunized mice (Fig. 2 – dashed bars) as compared with pre-immunization animals tests (Fig. 2 – grey bars). Notably, mice that did not receive any plasmid immunizations displayed average exercise times (Fig. 2 – dashed bars) equal to those of age-matched mice immunized with the empty plasmid pcDNA3 (Fig. 2 – white bars). So this decrease might reflect the aging of the mice.

In addition, WT and P2×7^{-/-} animals immunized with pcDNA3-hM₂ (Fig. 2 – black bars) displayed a significant reduction in the exercise times when compared with animals immunized with pcDNA3 at the 40th week post-immunization (Fig. 2 – white bars). This drop should be interpreted as a cardiac impairment in the M₂AChR WT group like that which we have previously described in BALB/c animals²².

Figure 3. Morphometric analysis of the heart. Hearts of WT and P2X7^{-/-} mice, immunized with pcDNA3 or pcDNA3 M₂AChR, were collected and analyzed at 40 weeks post-immunization. Upper panel: (A–D) Representative LV myocardial cross section micrographs of hearts from animals of each group at 40 weeks post-immunization. Scale bar, 2 cm. Lower panel: (E) Left Ventricle (LV) area ratio between the area of the cross-section of lumen and the total area of the cross-section of the heart. Black bars represent M₂AChR groups and white bars pcDNA3 groups. The letter **a** indicates a comparison between the WT pcDNA3 and WT M₂AChR groups, while letter **b** indicates a comparison between the P2X7^{-/-} pcDNA3 and P2X7^{-/-} M₂AChR groups. N = 5, p < 0.05 was considered statistically significant.

Moreover, M₂AChR P2X7^{-/-} mice also presented a reduction in exercise time, suggesting that these mice may also have developed a similar pathology, even in the presence of low M₂AChR auto-antibody titers.

Morphometric analysis. The exercise intolerance previously observed could be a consequence of a commitment at cardiac function or/and morphology. To investigate this hypothesis, heart morphological analysis was performed at the 40th week post-immunization. As shown in Fig. 3, heart samples from M₂AChR WT and P2X7^{-/-} groups displayed an enlargement in the lumen internal area of left ventricle cross section (Fig. 3 - panels B and D) as compared to the pcDNA3 control groups (Fig. 3 - panels A and C).

One of the typical features of DCM is a significant left ventricle dilation and wall thinning. When this effect is observed the ratio between the lumen internal area and total area of left ventricle increases³³. These two measurements were evaluated by using ImageJ software and as seen in the graph at Fig. 3 (lower panel). Both WT and P2X7^{-/-} animals of the M₂AChR group (Fig. 3, black bars) showed LV area ratios (lumen/total) around three times higher than pcDNA3 control animals (Fig. 3 - white bars).

Electrocardiographic analysis. The electrical activity of the mice was assessed by electrocardiography (ECG) during the pre-immunization period and at the 5th, 10th, 20th and 40th weeks post-immunization as shown in Table 1. No statistically significant RR interval differences were observed between pcDNA3 and M₂AChR WT mice group, although the Two-way ANOVA statistic test showed an effect over the weeks (p < 0.001). Taking into account the P2X7^{-/-} animals, it was noted that the M₂AChR P2X7^{-/-} group tended to be more bradycardic than animals belonging to the pcDNA3 P2X7^{-/-} control group. This decrease in RR interval reflected at heart rate was statistically different at the 10th week post-immunization when Bonferroni's post test was used.

Nevertheless, P2X7^{-/-} knockout mice already showed higher heart frequencies in the pre-immunization tests when compared with WT animals. This profile was maintained in the pcDNA3 P2X7^{-/-} mice over the experimental time, as seen by RR interval values frequently smaller than those presented by pcDNA3 WT mice, notably at 10th week post-immunization. P2X7^{-/-} M₂AChR mice did not keep the profile of high cardiac rates. Immunization of P2X7^{-/-} mice with pcDNA3-hM₂ plasmid gradually led to a decrease in the heart rate of this group, reaching values close to those of WT mice groups (Table 1).

Regarding the duration of the QT interval corrected for heart rate (QTc), no differences in the WT group were observed. When this parameter was analyzed by Two-way ANOVA hypothesis statistical test comparing WT and P2X7^{-/-} groups, P2X7^{-/-} mice displayed a longer QTc interval (p < 0.05), indicating defects in the depolarization of ventricles in this group, independently of pcDNA3-hM₂ immunization (Table 1).

Regardless of their immunization status, P2X7^{-/-} mice displayed a displacement of the ST interval, forming an ST depression in the electrocardiogram when compared to WT mice (p < 0.001). This

Wild Type									
	0 wks p.i.	5 wks p.i.		10 wks p.i.		20 wks p.i.		40 wks p.i.	
		pcDNA3	M ₂ AChR	pcDNA3	M ₂ AChR	pcDNA3	M ₂ AChR	pcDNA3	M ₂ AChR
RR interval (ms)	246.47 ± 22.78	225.33 ± 14.23	260.94 ± 42.24	262.98 ± 11.97	220.70 ± 13.65	175.78 ± 30.50	181.16 ± 56.15	268.85 ± 38.12	250.80 ± 18.90
Heart Rate (BPM)	248.11 ± 34.94	245.33 ± 43.20	232.30 ± 35.42	222.63 ± 13.17	251.96 ± 40.91	306.80 ± 65.03	342.26 ± 95.11	213.77 ± 24.17	229.53 ± 43.39
QRS interval (ms)	10.35 ± 2.26	11.22 ± 0.86	9.46 ± 1.07	10.38 ± 0.95	9.07 ± 0.59	11.07 ± 0.62	10.56 ± 1.09	11.03 ± 1.42	11.31 ± 1.13
QTc interval (ms)	44.00 ± 4.29	39.39 ± 6.30	40.60 ± 5.12	44.24 ± 1.85	45.23 ± 4.17	57.80 ± 12.86	56.68 ± 13.24	63.66 ± 18.29	57.05 ± 5.47
ST Height (mV)	0.15 ± 0.07	0.09 ± 0.07	0.11 ± 0.01	0.08 ± 0.01	0.19 ± 0.04 ^a	0.06 ± 0.04	0.10 ± 0.02	0.13 ± 0.04	0.10 ± 0.05
JT interval (ms)	11.41 ± 2.08	11.89 ± 6.25	11.12 ± 1.58	12.30 ± 1.80	12.79 ± 1.49	14.79 ± 1.24	12.27 ± 3.48	18.47 ± 5.50	17.44 ± 1.92
P2×7^{-/-}									
RR interval (ms)	189.63 ± 16.24 ^e	192.15 ± 16.38	208.20 ± 16.36 ^d	193.43 ± 51.37 ^c	241.83 ± 25.87 ^b	152.52 ± 31.71	182.00 ± 14.35	244.06 ± 17.43	239.48 ± 10.43
Heart Rate (BPM)	311.19 ± 30.14 ^e	282.78 ± 73.05	287.18 ± 20.29	353.47 ± 32.13 ^c	235.90 ± 21.21 ^b	390.06 ± 85.31	303.83 ± 13.45	274.57 ± 31.17	252.97 ± 5.84
QRS interval (ms)	8.88 ± 2.03	11.64 ± 3.05	9.17 ± 2.19	9.81 ± 1.37	10.73 ± 3.40	9.98 ± 1.51	10.43 ± 2.07	10.05 ± 2.39	12.89 ± 2.52
QTc interval (ms)	48.80 ± 5.05	52.58 ± 11.01	42.87 ± 4.61	61.00 ± 18.85 ^c	56.19 ± 6.87	63.00 ± 2.79	61.40 ± 10.34	58.20 ± 8.26	57.02 ± 6.16
ST Height (mV)	0.06 ± 0.06 ^c	0.00 ± 0.08	-0.03 ± 0.08 ^d	-0.01 ± 0.04	-0.02 ± 0.10 ^d	-0.01 ± 0.09	-0.07 ± 0.03 ^d	-0.01 ± 0.09 ^c	-0.01 ± 0.11
JT interval (ms)	11.18 ± 3.11	11.51 ± 6.98	9.43 ± 1.28	14.33 ± 6.04	15.11 ± 4.32	15.34 ± 1.69	13.04 ± 3.90	18.23 ± 4.26	15.00 ± 2.50

Table 1. Electrocardiogram recordings in Wild Type (WT) and P2×7^{-/-} immunized mice. Comparison between WT pcDNA3 and WT M₂AChR and between P2×7^{-/-} pcDNA3 and P2×7^{-/-} M₂AChR are marked with the letters **a** and **b**, respectively. Comparison between WT pcDNA3 and P2×7^{-/-} pcDNA3 and between WT M₂AChR and P2×7^{-/-} M₂AChR are marked by the letter **c** and **d**, respectively. Comparison between WT and P2×7^{-/-} previously immunization scheme was marked by letter **e**. $p < 0.05$ was considered statistically significant difference. N = 10. Wks p.i. – Weeks post-immunization.

alteration presented by P2×7^{-/-} mice was not accompanied by drastic change in JT interval duration (Table 1).

It is noteworthy that no arrhythmias were observed in the WT or P2×7^{-/-} mice groups. Examples of the ECG traces of one representative animal belonging to each of the four immunized groups at the 10th week post-immunization can be seen in Supplementary Figure S1.

The above data showed that P2×7^{-/-} mice developed DCM-like disease regardless of the reduced production of antibodies. These data suggest that other immune-related mechanisms may be involved in triggering DCM in the absence of P2×7 receptors. It is therefore important to test whether the transfer of anti-M₂AChR WT serum can induce the development of DCM in P2×7^{-/-} animals as they do in WT animals.

Serum containing anti-M₂AChR antibodies from WT immunized mice, at 10th week post-immunization, was transferred to naive WT and P2×7^{-/-} recipient mice. After ten weeks, recipient mice were subject to heart morphometric analysis and ECG exams.

The presence of anti-M₂AChR antibody led to an increase in the heart size and a change in its format from an ellipsoidal to a more rounded shape in WT and P2×7^{-/-} animals when compared to their respective control groups suggesting that recipient mice may develop antibody-induced DCM (Supplementary Figure S2 A–D). Analyzing myocardial cross section micrographs it was possible to observe a tendency in the ratio of heart LV lumen area to increase in WT and P2×7^{-/-} animals that received serum from WT M₂AChR, being more prominent in animals from the WT group (Supplementary Figure S2 E).

The analysis of ECGs (Table 2) detected an increase in the cardiac frequency and JT interval of WT recipient mice, when compared to those that received serum from pcDNA3 immunized WT mice. P2×7^{-/-} mice that received anti-M₂AChR serum also displayed lower heart rates than their respective control groups, as already seen when they were immunized with pcDNA3-hM2 plasmid, indicating that these mice were also susceptible to the effect of anti-M₂AChR serum.

Differently to what we have observed in the above experiments, when serum from M₂AChR-immunized P2×7^{-/-} mice, shown in Fig. 1 to have lower titers of anti-M₂AChR, was transferred into WT or P2×7^{-/-} unimmunized mice, we did not observe DCM-like changes in either heart morphology or the ECG (Supplementary Table S1). These results indicate that autoimmune components other than anti-M₂AChR are involved in the development of DCM in P2×7^{-/-} mice under our experimental conditions.

Characterization of Treg spleen population. Regulation of immune responses to self and foreign antigens is critically dependent on Treg function. These cells are characterized by the expression of transcription factor FoxP3 in the CD4⁺ T cell population³⁴. We have therefore decided to investigate the frequency of Treg cells in the spleen of pcDNA3 and M₂AChR mice at the 40th week post-immunization.

	Wild Type Recipient	P2 $\times$ 7 ^{-/-} Recipient	pcDNA3 Wild type serum	M ₂ AChR Wild type serum
	pcDNA3 Wild type serum	M ₂ AChR Wild type serum		
RR Interval (ms)	210.45 $\pm$ 45.60	138.97 $\pm$ 10.53 ^a	147.70 $\pm$ 21.24 ^c	168.77 $\pm$ 27.33
Heart Rate (BPM)	337.20 $\pm$ 81.22	379.23 $\pm$ 13.70	384.23 $\pm$ 52.29 ^c	359.15 $\pm$ 55.39
PR Interval (ms)	40.44 $\pm$ 8.55	34.84 $\pm$ 8.68	39.13 $\pm$ 1.48	40.10 $\pm$ 0.45
QRS Interval (ms)	9.63 $\pm$ 1.37	13.21 $\pm$ 1.25	13.86 $\pm$ 1.97	13.86 $\pm$ 1.52
QTc Interval (ms)	66.68 $\pm$ 1.13	85.43 $\pm$ 2.08	83.39 $\pm$ 2.91	74.89 $\pm$ 2.52
ST Height (mV)	0.020 $\pm$ 0.054	0.115 $\pm$ 0.057	-0.050 $\pm$ 0.022	-0.015 $\pm$ 0.070 ^d
JT interval	12.91 $\pm$ 1.14	19.07 $\pm$ 0.76 ^a	16.88 $\pm$ 6.85	12.24 $\pm$ 2.92 ^d

Table 2. Electrocardiogram recordings in mice that received pcDNA3 or M₂AChR WT serum 10 weeks post-serum transfer. Comparison between WT pcDNA3 and WT M₂AChR and between P2 $\times$ 7^{-/-} pcDNA3 and P2 $\times$ 7^{-/-} M₂AChR are marked with the letters a and b, respectively. Comparison between WT pcDNA3 and P2 $\times$ 7^{-/-} pcDNA3 and between WT M₂AChR and P2 $\times$ 7^{-/-} M₂AChR are marked by the letter c and d, respectively. $p < 0.05$ was considered statistically significant difference. N = 5.

Representative cytometry data of individual mouse in each experimental group and gate strategy used in our analyses are shown in Fig. 4(A–D). The total number of spleen cells (data not shown) and the percentages of total CD4⁺ T cells (Fig. 4E) showed no significant differences between the four experimental mouse groups.

In WT mice, the percentage of total Treg cells (CD4⁺FoxP3⁺), as well as the percentage of the CD25⁻ Treg subpopulation, were not significantly different in M₂AChR group when compared to the pcDNA3 control group (Fig. 4 - F and G - 1st and 2nd columns).

On the other hand, in P2 $\times$ 7^{-/-} mice the frequency of total CD4⁺FoxP3⁺ cells showed a small but significant increase when compared with their respective WT group at the 40th week post-immunization (Fig. 4F - 3rd column and 4th column). A more detailed analysis showed that P2 $\times$ 7^{-/-} pcDNA3 control group had significantly higher percentage of the CD25⁻ subset of Tregs (Fig. 4G - 3rd column) compared to WT controls (Fig. 4G - 1st column). Although the levels of this population are diminished in P2 $\times$ 7^{-/-} mice immunized with the plasmid coding M₂AChR (compared to the pcDNA3 control group), the frequency of CD25⁻FoxP3⁺ Tregs is significantly higher in P2 $\times$ 7^{-/-} than in WT mice (Fig. 4 - G - 2nd and 4th columns).

These data show that although P2 $\times$ 7^{-/-} mice have an higher frequency of Tregs in the spleen, compared to WT mice, the majority of Tregs in pcDNA3-immunized P2 $\times$ 7^{-/-} mice have a CD25⁻ phenotype, which have been associated to an unstable subset of Tregs³⁵.

IL-1 β production in the hearts of M₂AChR mice is dependent on P2 $\times$ 7. To determine the participation of the innate immune system in the establishment of the DCM, we analyzed the dosage of IL-1 β in cardiac homogenates. As shown in Fig. 5, the level of IL-1 β in the heart at the 20th week post-immunization was higher in WT mice immunized with pcDNA3-hM₂ plasmid as compared to pcDNA3-immunized-mice, a difference that was not observed in the hearts of P2 $\times$ 7^{-/-} mice. This pattern of IL-1 β production is consistent with other experimental models where P2 $\times$ 7^{-/-} were used³⁶. This profile was not maintained at the 40th week post-immunization when control and immunized mice displayed low levels of IL-1 β .

IFN γ production peaks at the 20th week post-immunization and is not dependent on P2 $\times$ 7. The participation of IFN γ in the cardiomyopathy induced by immunization with pcDNA3-hM₂ plasmid was assessed through the dosage of this cytokine in heart homogenates (Fig. 6). At the 5th and 10th weeks post-immunization there were no significant differences amongst the four experimental groups. However at the 20th week the hearts of M₂AChR WT mice displayed an increased level of IFN γ when compared to the pcDNA3 control group and to the same group at the 5th and 10th weeks post-immunization. In the hearts of P2 $\times$ 7^{-/-} mice, an increased level in IFN γ was observed in both pcDNA3-immunized mice and, more significantly, M₂AChR-immunized mice. At the 40th week post-immunization, these values fell drastically in all groups with the P2 $\times$ 7^{-/-} M₂AChR mice displaying the lowest levels of IFN γ (Fig. 6).

IL-17 production in the hearts of M₂AChR mice is dependent on P2 $\times$ 7. We also analyzed the expression of IL-17 in the hearts during the period from the 5th to the 40th week post-immunization (Fig. 7). Starting at the 10th week post-immunization animals from the P2 $\times$ 7^{-/-} groups presented lower levels of IL-17 when compared to WT groups. At the 20th week post-immunization the highest IL-17 levels were detected in the hearts of M₂AChR-immunized WT mice. Although no statistically significant

Figure 4. Frequency of CD4⁺ T lymphocytes and Treg in the spleen of WT and P2 $\times$ 7^{-/-} immunized mice. Left panel (A–D), representative cytometry data and gate strategy of (A) WT pcDNA3, (B) WT M₂AChR, (C) P2 $\times$ 7^{-/-} pcDNA3 and (D) P2 $\times$ 7^{-/-} M₂AChR individual mouse spleen cell analyzes. Mean and SD values of the frequency of (E) total CD4⁺ T cells; (F) total CD4⁺CD25⁺ Treg among CD4⁺ T cells and (G) CD4⁺CD25⁺ Treg subset among CD4⁺ T cells in each experimental group. Spleens of 5 mice in each group were individually analyzed at day 40 after immunization. Staining was performed as described in the Methods section. The letter **b** indicates a comparison between the P2 $\times$ 7^{-/-} pcDNA3 and P2 $\times$ 7^{-/-} M₂AChR groups. Bars with **c** indicate the comparison between the WT pcDNA3 and P2 $\times$ 7^{-/-} pcDNA3 groups and with **d** indicate a comparison between the WT M₂AChR and P2 $\times$ 7^{-/-} M₂AChR groups. N = 5.

difference in IL-17 levels existed between M₂AChR-immunized and pcDNA3-immunized WT groups it seemed slightly higher in M₂AChR WT mice ($p = 0.06$). IL-17 levels decreased at the 40th week in all groups but both P2 $\times$ 7^{-/-} immunized groups showed significantly lower levels than their corresponding WT counterparts. It is noteworthy that IL-17 and IL-1 β production in the heart followed the same profile, suggesting an association between these two cytokines in the progression of DCM under our experimental conditions.

Discussion

Here we first demonstrated that C57BL/6J WT mice immunized with the M₂AChR sequence developed similar DCM characteristics as previously described for BALB/c mice²². Additionally, the employment of P2 $\times$ 7^{-/-} mice allowed us to gain insight not only into the immune mechanism of DCM development, but also the involvement of the P2 $\times$ 7 receptor in cardiac function. M₂AChR-immunized P2 $\times$ 7^{-/-} mice only produced anti-M₂AChR-el₂ antibodies at a later time and at a more attenuated level than the M₂AChR-immunized WT mice. This result indicates that the lack of P2 $\times$ 7 receptors impairs at least one important step in the chain of events, that includes antigen capture and processing by antigen-presenting

Figure 5. IL-1 β production in the heart during 40 weeks post-immunization. The levels of IL-1 β were analyzed directly in heart homogenate without any additional stimulus and expressed as pg of cytokine per mg of total protein at the 5th, 10th, 20th, and 40th weeks post-infection. Black bars represent the M₂AChR-immunized groups and white bars represent the pcDNA3-immunized control groups. Bar with a indicates statistically significant differences between WT pcDNA3 and WTM₂AChR groups. The letter d indicates a comparison between the WT M₂AChR and P2 $\times$ 7^{-/-} M₂AChR groups. N = 5, p < 0.05 was considered statistically significant.

Figure 6. IFN γ production in the heart during 40 weeks post-immunization. The levels of IFN γ were analyzed using heart homogenate samples. Black bars represent the M₂AChR-immunized groups and white bars represent the pcDNA3-immunized control groups. Bar with b indicates statistically significant differences between P2 $\times$ 7^{-/-} pcDNA3 and P2 $\times$ 7^{-/-} M₂AChR groups and with d indicates a comparison between the WT M₂AChR and P2 $\times$ 7^{-/-} M₂AChR groups. N = 5, p < 0.05 was considered statistically significant.

Figure 7. IL-17 production in the heart during 40 weeks post-immunization. The levels of IL-17 were analyzed using the same protocol as previously described for obtaining the dosage of IL-1 β . Black bars represent the M₂AChR-immunized groups and white bars represent the pcDNA3-immunized control groups. Bars with c indicate the comparison between the WT pcDNA3 and P2 $\times$ 7^{-/-} pcDNA3 groups and with d indicate a comparison between the WT M₂AChR and P2 $\times$ 7^{-/-} M₂AChR groups. N = 5, p < 0.05 was considered statistically significant.

cells, efficient antigen presentation to T cells and stimulation of M₂AChR-specific B lymphocyte clones. One possibility is the need of functional expression of P2×7 receptors for efficient antigen processing and presentation by dendritic cells, as previously proposed by others^{26,37}.

Despite the differences in the M₂AChR antibody production between WT and P2×7^{-/-} mice, M₂AChR P2×7^{-/-} animals also developed signs of DCM when compared with their pcDNA3 controls, such as a reduction in exercise time and an increase in the lumen of the left ventricle at the 40th week after the first immunization scheme.

The development of functional and morphological characteristics of DCM shown by the M₂AChR P2×7^{-/-} mice surprised us since the importance of autoantibodies in the development of autoimmune DCM has been firmly established in the literature³⁸. Besides this, a recent work showed that the treatment with the P2×7 receptor antagonist A740003 leads to an improvement in heart function of BALB/c male mice that develop autoimmune myocarditis after immunization with α myosin heavy chain²⁹.

One possible explanation for the development of DCM by P2×7^{-/-} M₂AChR-immunized mice would be a predisposition for the development of heart disease as these mice displayed a different electrocardiographic pattern to that observed for WT mice. To our knowledge this has not been previously reported in the literature. We described that P2×7^{-/-} animals presented a higher heart rate, longer QTc interval and superior ST depression than the WT mice.

The higher heart rate can be the result of the lack of P2×7 receptor at the sinoatrial node and/or in the nervous system. But its role in pacemaker activity has not been studied^{39,40}. In addition, ATP and adenosine have negative chronotropic and dromotropic effects mediated by complex neuronal pathways involving P2X and P1 receptors and the binding of ATP to purinergic receptor that initiates a cascade facilitating the development of arrhythmias^{29,41}.

In all experiments, unimmunized and pcDNA3-immunized P2×7^{-/-} mice spontaneously displayed higher ST depression in their ECG. This depression was not dependent on the presence of anti-M₂AChR antibodies. Although few articles describe this electrocardiographic finding in mice associated with signs of cardiac ischemia, in humans it is commonly related to hypokalemia⁴². Transgenic mice overexpressing erythropoietin (Epo-TG6 mice) are highly intolerant to exercise despite showing an increase in myocardial contraction force and having a ST depression after injection of norepinephrine, a ST profile that arises spontaneously in the P2×7^{-/-} mice. This change preceded acute heart failure, demonstrating a barrier between myocardial oxygen demand and delivery⁴³. We thus conclude that together with the increased heart frequency, the presence of ST depression suggests that P2×7^{-/-} mice have a predisposition to develop heart dysfunction.

Although the role of the P2×7 receptor in the heart is not completely clear yet, our data confirm its importance for the proper functioning of this organ, mainly regarding the electrical rhythm and conduction system. The cardiac differences between WT and P2×7^{-/-} mice led to the emergence of new issues that need further studies: (1) Are there any correlations between the development of heart disease in humans and gain or loss of function by P2×7 receptor? (2) Do patients with heart disease develop long-term changes in P2×7 receptor functionality? The answer to these questions would help to prevent and treat some cases of cardiac disease.

The transfer of anti-M₂AChR antibodies from previously immunized M₂AChR WT mice to P2×7^{-/-} naïve mice, as well as the transfer of serum from M₂AChR P2×7^{-/-} mice that developed DCM, but did not display high titers of anti-M₂AChR antibodies, did not induce the development of DCM in either WT or P2×7^{-/-} mice. These results suggest that other M₂AChR-specific immune-related parameters, most likely a cellular immune response, may be important in the development of DCM in immunized P2×7^{-/-} mice. The possibility that this cellular component is also present in WT mice should also be considered.

We therefore analyzed other parameters of the immune response during the 40th week experimental period. We first analyzed Treg cell percentages in the spleens of WT and P2×7^{-/-} immunized mice. It is known that the presence of FoxP3⁺ cells protect against the development of autoimmune myocarditis in a different model⁴⁴. In addition, the activation of the purinergic P2×7 receptor by ATP triggers a pro-inflammatory cascade, which induces pathways of regulatory T-cell death⁴⁵. Accordingly, here we showed that P2×7 deficiency in C57BL/6J mice led to an increase in the percentage of FoxP3⁺CD4⁺ cells in the spleen compared to the WT group. A more detailed analysis of the IL-2 receptor alpha-chain (CD25) expression in the FoxP3⁺CD4⁺ sub-population demonstrated that P2×7^{-/-} mice displayed a significantly decreased percentage of CD4⁺CD25⁺FoxP3⁺ cells and significantly higher percentage of FoxP3⁺CD25⁻ cells. Although the origin and function of CD4⁺FoxP3⁺CD25⁻ cells is still quite controversial, it is believed that such cells would be more unstable with a higher tendency to lose the expression of FoxP3 and differentiate into effector T cells^{35,46–48}. Thus, although we found no differences in Treg cell frequency between WT M₂AChR and WT pcDNA3 groups, the P2×7^{-/-} pcDNA3 and M₂AChR groups display a significant higher percentage of Tregs (compared to their respective WT group), due to higher frequency the unstable FoxP3⁺CD25⁻Treg sub-population, suggesting a decreased suppressor Treg cell activity or a higher conversion to effector cells in the M₂AChR -immunized P2×7^{-/-} mice. Notably, CD4⁺Foxp3⁺CD25⁻ Tregs were found in type 1 diabetes mellitus⁴⁹ and in systemic lupus erythematosus patients and some evidence suggest that these are dysfunctional Tregs⁴⁶. However, FoxP3 expression in humans and mice differs in some aspects, as activated human T cells transiently express Foxp3 without

the acquisition of suppressor potential. Therefore, further studies are needed to better clarify the identity and role of $CD4^+Foxp3^+CD25^-$ cell population in autoimmunity.

The production of IL-17 at the 20th week post-immunization increased in the M_2AChR -immunized WT heart but not in the $P2\times 7^{-/-}$ hearts, being reduced over a longer measured time. This increase could be one of the factors that contribute to the development of the disease in wild type mice as its influence has been shown in pro-fibrotic processes, as well as cardiac remodeling. After the establishment of dilatation the levels of IL-17 decrease, appearing to be essential to install a more severe disease feature^{14,15}.

A study conducted with mononuclear cells isolated from patients infected with *T. cruzi* revealed that patients with moderate cardiomyopathy showed the highest levels of this cytokine, while patients classified as severe showed reduced levels of IL-17²¹. Moreover, it was demonstrated in mice with chronic dilated cardiomyopathy induced by *T. cruzi* infection that reduction of IL-17 levels, through the administration of anti-IL17, worsened the symptoms of the disease²⁰. Therefore the reduction of IL-17 levels, or even the absence of its receptor-mediated signaling, could lead to a serious and fatal cardiomyopathy in mice⁵⁰. However, the role of IL-17 appears to be strictly dependent on the context of other cytokines¹⁶.

We showed that IL-1 β followed a similar production pattern as the one presented by IL-17. At the 20th week post-immunization the production of IL-1 β was higher in M_2AChR WT but not in the M_2AChR $P2\times 7^{-/-}$. A defect in the production of IL-1 β in $P2\times 7^{-/-}$ mice has been described in several experimental models^{23,27}. In recent years, it has been demonstrated that IL-1 β can stimulate the production of IL-17 in memory and naïve $CD4^+$ T-cells. In addition, it has been shown that the pathway activated through IL-1R1 is necessary for the early differentiation of $CD4^+$ Th17⁵¹ and that IL-1 β and IL-23 induce the production of IL-17 in $\gamma\delta$ cells. Moreover, $\gamma\delta$ cells generate a loop amplification with $CD4^+$ cells through an increase in the secretion of IL-17 in $CD4^+$ cells⁵². In conclusion, the absence of ATP signaling in $P2\times 7$ receptor knockout mice provides a signaling framework to support the small production of IL17 and IL-1 β .

The production of IFN γ increased in the M_2AChR WT and $P2\times 7^{-/-}$ hearts at the 20th week post-immunization, and, contrary to IL-1 β , this effect was more remarkable in the $P2\times 7^{-/-}$ mice. High IFN γ levels have been described in several models of heart disease, mainly in Chagas' disease^{19,53}. IFN γ may increase the infiltration of inflammatory cells and the secretion of other pro-inflammatory cytokines leading to a significant down regulation of α -smooth muscle actin, disarranging the healing process, inducing myosin heavy chain degradation and cardiac remodeling^{54,55}. High serum levels of IFN γ in overexpressing transgenic mice lead to cardiac dysfunction which culminates in the development of cardiomyopathy⁵⁶. But in models of experimental autoimmune myocarditis, mainly induced by anti-myosin antibodies, IFN γ played a cardioprotective role, where mice that were deficient in IFN γ (*Ifn γ ^{-/-}*) developed a severe cardiomyopathy^{16,57}.

Significant cardiac abnormalities were observed in M_2AChR WT and M_2AChR $P2X^{-/-}$ mice that had peak production of IFN γ at the 20th week post-immunization. These results highlight that the mechanisms which WT and $P2\times 7^{-/-}$ mice immunized with pcDNA3-hM2 plasmid develop cardiomyopathy are through different pathways. One involves anti M_2AChR antibodies and higher IL1 β and IL17 cytokine levels, absent in the $P2\times 7^{-/-}$ mice, and the other requires higher levels of IFN γ . M_2AChR WT mice appear to be more dependent on the presence of anti- M_2AChR antibodies, while M_2AChR $P2\times 7^{-/-}$ mice are more dependent on the mechanisms involving IFN γ described above. The involvement of IFN γ may be indicative of a T cell-mediated anti- M_2AChR phenomenon. More experiments are needed to clarify this mechanism. In summary, our results confirm that the presence of anti- M_2AChR antibodies lead to the development of DCM in WT mice. In addition, $P2\times 7^{-/-}$ mice, which contain low titers of such antibodies, can also develop the disease, but in this case a cell-mediated immune response may become more prevalent. We also confirmed that IL-17 levels are inversely correlated with the severity of disease after establishment of the disease, which occurs primarily during the first 20 weeks post-immunization. This cytokine could participate in the cardiac remodeling process that triggers the DCM. In its absence, as was observed in the knockout mice, other factors (such as electrical pre-disposition) and cytokines (IFN γ) become more dominant factors in the development of the disease. Therefore, a precise balance of the immune response where a complex network of factors has been generated creates the conditions for the development of DCM.

Methods

Study design. Seven-week-old female C57BL/6J wild type (from Multidisciplinary Center for Biological Research - CEMIB, Campinas, São Paulo, Brazil) and Purinergic $P2\times 7$ receptor knockout mice ($P2\times 7^{-/-}$) (from Jackson Laboratories - JAX[®] Mice and Services, Bar Harbor, Maine 04609, USA), weighing $16.0g \pm 0.7g$ were randomly allocated to one of the following treatment groups: (1) wild type (WT) immunized with pcDNA3 plasmid (WT pcDNA3 group), (2) WT immunized with pcDNA3-hM₂ (WT M_2AChR group), (3) $P2\times 7^{-/-}$, immunized with pcDNA3 plasmid ($P2\times 7^{-/-}$ pcDNA3 group) and (4) $P2\times 7^{-/-}$, immunized with pcDNA3-hM₂ plasmid ($P2\times 7^{-/-}$ M_2AChR group) ($n = 10$ in each group). The animals from each group were individually identified and maintained at the local animal facility (Laboratory of Transgenic Animals - LAT, Institute of Biophysics Carlos Chagas Filho - IBCCF, UFRJ, Rio de Janeiro, Brazil). This study was approved by the Ethics Committee on the Use of Animals of Health Sciences Center of Federal University of Rio de Janeiro, Brazil (CEUA/CCS/UFRJ, CONCEA registered #01200.001568/2013.87, approved protocol IBCCF 041). All animals received humane care

in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of Sciences, USA, and National Council for Controlling Animal Experimentation, Ministry of Science, Technology and Innovation (CONCEA/MCTI), Brazil.

The experimental mice, either native or P2×7KO, used in the present work were genotyped prior each experiment. For this, the genomic DNA from mice’ tail were extracted and submitted to PCR reaction using specific set of primers (native for wild type and neomycin for P2×7^{-/-}). DNA samples corresponding to each animal was subjected to two PCR reactions, one with primers to amplify a fragment corresponding to the P2×7 native sequence and one with primers for amplification of a region containing part of the P2×7 neomycin chimera sequence, obtained by the replacement of the region of the gene encoding Cys506 to Pro532 with the neomycin resistance gene⁵⁸. The amplification of a unique fragment of 418 bp corresponding to the native sequence was observed only when genomic DNA from wild type was used as template. None of the samples of genomic DNA originated from P2×7^{-/-} mice showed PCR product amplification using these native primers. Contrarily, these latter samples showed amplification bands of 510 bp at agarose gels, only in reactions where the 3’ neomycin primer was used for amplification) confirming that P2×7^{-/-} animals carry the mutant allele.

The immunizations were performed using a helium-driven gene gun (Bio-Rad, Hercules, CA, USA) as previously described²². Each mouse was primed and boosted two more times, with a 14 day interval between boosts (days 0, 14 and 21). The immunization scheme was repeated starting at the 20th week after the first immunization scheme. All procedures performed with these mice are described in detail in subsequent sessions and summarized in Supplementary Figure S3.

Sera collection and enzyme-linked immunosorbent assays (ELISA). Blood samples were collected from the mouse orbital sinus under anesthesia with ketamine 60 mg/Kg and xilazine 3 mg/Kg at a mean interval of 4 weeks over the course of 40 weeks (immune samples), including samples prior to the first immunizations (pre-immune samples). For serum separation the samples were maintained at 25°C, overnight, centrifuged twice at 5,000 × g for 15 minutes and the clear serum layer was stored in approximately 200 µL at -80°C. The quantification of IgG antibody titers was performed by enzyme-linked immunosorbent assay (ELISA) using a synthetic peptide corresponding to M₂AChR-el₂ (1₆₈VRTVEDGECYIQFFSNAAVTFGTAI₁₉₂) as previously described²².

Cardiac exercise testing analysis. The animals were subjected to ergometric tests before immunization (seven weeks old) and at the 35th week after the first immunization using a treadmill (Panlab, Cornella, Barcelona) with an adjustable speed and a 10° slope. The treadmill was equipped with electrodes, producing shocks of 0.5 mA activated when the animal tried to rest. Two days before the functional test, the mice were subjected to room recognition for 15 minutes at 17 cm/s. On the functional test day, the mice were placed in the treadmill chamber at a speed of 17 cm/s. Every 2 minutes, the speed was increased by 2 cm/s. The animals ran until exhaustion when the total time achieved was recorded.

Morphometric analysis. The pcDNA3 and M₂AChR mice were euthanized through cervical dislocation preceded by anesthesia with ketamine 60 mg/Kg and xilazine 3 mg/Kg. The heart of each animal was removed from base vessels while still mechanically active and immediately immersed in PBS (Phosphate-buffered saline). The apex and the base of each heart were removed and the remaining tissue was photographed. To quantify left ventricular dilation, the internal area and the total area of left ventricle cross section were measured using ImageJ software (version 1.45s, the National Institutes Health, USA). Subsequently, the relationship between these two measurements was plotted using GraphPad Prism (version 5 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com).

Electrocardiographic analysis. Electrocardiographic (ECG) evaluation was performed at the 5th, 10th, 20th and 40th weeks post-immunization. All animals were anaesthetized through intraperitoneal injection of ketamine 60 mg/Kg and xilazine 3 mg/Kg. After sedation, the animals were placed on a platform in the prone position. ECG was recorded by connecting the four limbs to a Bio Amp PowerLab 2/20 System (AD Instruments, Castle Hill, Australia), using the bipolar lead I configuration. The digitalized ECG signals were recorded and stored for posterior analysis using the LabChart 6 program (AD Instruments). The ECG analysis included the following measurements: heart rate, PR interval, P wave duration, RR interval, QT interval, QTc, QRS complex duration, ST height, JT interval and arrhythmia. The ECG recordings were obtained from each animal for 15 minutes and all recordings were performed in the morning period.

Serum Transfer. The serum collected from pcDNA3 and M₂AChR WT and P2×7^{-/-} immunized mice at the 5th and 10th weeks post-immunization, previously described above, were pooled and stored at -20°C until use. 8-week-old C57BL/6J female recipient mice (N = 5) received 100 µL of serum pool intravenously according to a regime of three transfers at intervals of 14 days. After 10 weeks post-transfer the recipient mice were subjected to ECG following the same specifications described before.

Regulatory T cell analysis. Treg cell analyses were performed by flow cytometry using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). The spleens were removed aseptically and mechanically dissociated in the presence of DMEM medium. The dissociated cells were centrifuged and the pellet was resuspended in hemolytic solution, followed by additional centrifugation. The pellet was resuspended in DMEM medium supplemented with 5% fetal bovine serum and the numbers of splenocytes were counted using a Neubauer chamber. Erythrocyte-depleted spleen cells (2×10^6 cells) were incubated with anti-CD4-FITC (BD Pharmingen) and anti-CD25-APC (BD Pharmingen) at 4°C for 30 minutes, followed by washing with FACS Buffer (PBS, 0.5% BSA and 0.01% NaN_3). After this, cells were fixed and permeabilized using the Mouse Regulatory T-Cell Staining Kit (eBioscience) and stained with anti-mFoxP3-PE (eBiosciences), according to the manufacturer's instructions. The data were analyzed using CELLQUEST™ Pro Software (BD Biosciences).

Cytokine quantification using ELISA. IL-17 (Mouse IL-17 ELISA, Bender Med System, Vienna, Austria), IFN γ (Murine IFN- γ Mini ELISA Development Kit, PepoTrech, Rocky Hill, NJ, United States) and IL-1 β (Mouse IL-1 β ELISA Set, BD Bioscience, Franklin Lakes, NJ, USA) expression in the heart were analyzed using specific ELISA kits. All procedures were performed following the manufacturers' recommendations.

Heart tissue fragments (approximately 100 mg) were homogenized using an Ultra-Turrax T25 basic homogenizer (IKA Werke GmbH & Co. KG, Staufen, Germany) in cold lysis buffer (50 mM HEPES, 1 mM MgCl_2 and 10 mM EDTA, pH 7.4 on ice). The macerated tissue was centrifuged ($15,000 \times g$ for 15 minutes at 4°C) and the supernatants were collected for cytokine quantification. All assays were performed in triplicate.

Statistical analysis. The statistical significance was evaluated using two-way analysis of variance (ANOVA) with Bonferroni's multiple comparisons test for the comparison between groups. The differences between parameters obtained at pre-immunization compared with those obtained at 5, 10, 20 and 40th weeks post-immunization are marked by asterisks (* $p < 0.05$; ** $p < 0.01$; and *** $p < 0.001$). Comparisons between WT pcDNA3 and WT M $_2$ AChR and between P2 $\times 7^{-/-}$ pcDNA3 and P2 $\times 7^{-/-}$ M $_2$ AChR were marked with the letters **a** and **b**, respectively. Comparisons between WT pcDNA3 and P2 $\times 7^{-/-}$ pcDNA3 and between WT M $_2$ AChR and P2 $\times 7^{-/-}$ M $_2$ AChR were marked by the letter **c** and **d**, respectively. Statistically significant differences between WT and P2 $\times 7^{-/-}$ before immunization (0 weeks post-immunization) were marked by letter **e**. In these cases $p < 0.05$ was considered statistically significant. These analyses were performed using GraphPad Prism 5.00 personal computer software. The graphs were plotted using the means $\pm$ S.D, except for anti-M $_2$ AChR- el_2 titer quantification that was represented by the means $\pm$ S.E.M.

References

- Sisakian, H. Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies. *Worl J Cardiol* **26**, 478–494 (2014).
- Modesto, K. & Sengupta, P. P. Myocardial mechanics in cardiomyopathies. *Prog Cardiovasc Dis* **57**, 111–124 (2014).
- Fu, L. X. *et al.* Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. *J Clin Invest* **91**, 1964–1968 (1993).
- de Oliveira, S. F., Pedrosa, R. C., Nascimento, J. H. M., de Carvalho, A. C. C. & Masuda, M. O. Sera from chronic chagasic patients with complex cardiac arrhythmias depress electrogenesis and conduction in isolated rabbit hearts. *Circulation* **96**, 2031–2037 (1997).
- Goin, J., Leiros, C. P., Borda, E. & Sterin-Borda, L. Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. *FASEB J* **11**, 77–83 (1997).
- Peter, J.-C. *et al.* Effects on heart rate of an anti-M $_2$ acetylcholine receptor immune response in mice. *FASEB J* **19**, 943–949 (2005).
- Baba, A. *et al.* Autoantibodies against M $_2$ -muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. *Eur Heart J* **25**, 1108–1115 (2004).
- Epelman, S., Liu, P. P. & Mann, D. L. Role of innate and adaptive immune mechanisms in cardiac injury and repair. *Nat Rev Immunol* **15**, 117–129 (2015).
- Domingues, H. S., Mues, M., Lassmann, H., Wekerle, H. & Krishnamoorthy, G. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. *PLoS One* **5**, e15531 (2010).
- Luger, D. *et al.* Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. *J Exp Med* **205**, 799–810 (2008).
- Damsker, J. M., Hansen, A. M. & Caspi, R. R. Th1 and Th17 cells. *Ann N Y Acad Sci* **1183**, 211–221 (2010).
- Lee, Y. K. *et al.* Late developmental plasticity in the T helper 17 lineage. *Immunity* **30**, 92–107 (2009).
- Wang, Y. *et al.* The Transcription Factors T-bet and Runx Are Required for the Ontogeny of Pathogenic Interferon- γ -Producing T Helper 17 Cells. *Immunity* **40**, 355–366 (2014).
- Baldeviano, G. C. *et al.* Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. *Circ Res* **106**, 1646–1655 (2010).
- Wu, L. *et al.* Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. *J Exp Med* **211**, 1449–1464 (2014).
- Barin, J. G. *et al.* Fatal eosinophilic myocarditis develops in the absence of IFN- γ and IL-17A. *J Immunol* **191**, 4038–4047 (2013).
- Afanasyeva, M. *et al.* Impaired up-regulation of CD25 on CD4 $^{+}$ T cells in IFN- γ knockout mice is associated with progression of myocarditis to heart failure. *Proc Natl Acad Sci USA* **102**, 180–185 (2005).
- Nogueira, L. G. *et al.* Myocardial gene expression of T-bet, GATA-3, Ror- γ , FoxP3, and hallmark cytokines in chronic chagas disease cardiomyopathy: an essentially unopposed T H 1-type response. *Mediators Inflamm* **2014**, 1–9 (2014).
- Pereira, I. R. *et al.* A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. *PLoS Pathog* **11**, e1004594 (2015).

20. da Matta Guedes, P. M. *et al.* IL-17 produced during *Trypanosoma cruzi* infection plays a central role in regulating parasite-induced myocarditis. *PLoS Negl Trop Dis* **4**, e604 (2010).
21. Guedes, P. M. M. *et al.* Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human chagas' disease. *PLoS Negl Trop Dis* **6**, e1630 (2012).
22. Giménez, L. E. *et al.* DNA immunizations with M2 muscarinic and $\beta 1$ adrenergic receptor coding plasmids impair cardiac function in mice. *J Mol Cell Cardiol* **38**, 703–714 (2005).
23. Lamkanfi, M. & Dixit, V. M. Mechanisms and functions of inflammasomes. *Cell* **157**, 1013–1022 (2014).
24. Burnstock, G. Purinergic signalling: pathophysiology and therapeutic potential. *Keio J Med* **62**, 63–73 (2013).
25. Rayah, A., Kanellopoulos, J. M. & Di Virgilio, F. P2 receptors and immunity. *Microbes Infect* **14**, 1254–1262 (2012).
26. Ghiringhelli, F. *et al.* Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 β -dependent adaptive immunity against tumors. *Nat Med* **15**, 1170–1178 (2009).
27. Pang, I. K., Ichinohe, T. & Iwasaki, A. IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8+ T cell responses to influenza A virus. *Nat Immunol* **14**, 246–253 (2013).
28. Rissiek, B., Haag, F., Boyer, O., Koch-Nolte, F. & Adriouch, S. ADP-Ribosylation of P2 $\times$ 7: a matter of life and death for regulatory T cells and natural killer T cells. *Curr Top Microbiol Immunol* **34**, 107–126 (2015).
29. Zempo, H. *et al.* A P2X7 receptor antagonist attenuates experimental autoimmune myocarditis via suppressed myocardial CD4+ T and macrophage infiltration and NADPH oxidase 2/4 expression in mice. *Heart Vessels*, **30**, 527–533 (2014).
30. Granado, M. *et al.* Altered expression of P2Y2 and P2 $\times$ 7 purinergic receptors in the isolated rat heart mediates ischemia-reperfusion injury. *Vascul Pharmacol*, **73**, 96–103 (2015).
31. Vessey, D. A., Li, L. & Kelley, M. P2 $\times$ 7 receptor agonists pre- and postcondition the heart against ischemia-reperfusion injury by opening pannexin-1/P2 $\times$ 7 channels. *Am J Physiol Heart Circ Physiol* **301**, H881–H887 (2011).
32. Mezzaroma, E. *et al.* The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. *Proc Natl Acad Sci* **108**, 19725–19730 (2011).
33. Spinale, F. G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. *Physiol Rev* **87**, 1285–1342 (2007).
34. Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. *Nat Immunol* **4**, 330–336 (2003).
35. Hori, S. Lineage stability and phenotypic plasticity of Foxp3+ regulatory T cells. *Immunol Rev* **259**, 159–172 (2014).
36. Miller, C. M. *et al.* The role of the P2 $\times$ 7 receptor in infectious diseases. *PLoS Pathog* **7**, e1002212 (2011).
37. Mutini, C. *et al.* Mouse dendritic cells express the P2 $\times$ 7 purinergic receptor: characterization and possible participation in antigen presentation. *J Immunol* **163**, 1958 (1999).
38. Nagatomo, Y. & Tang, W. W. Autoantibodies and Cardiovascular Dysfunction: Cause or Consequence? *Curr Heart Fail Rep* **11**, 1–9 (2014).
39. Barth, K. *et al.* Increased P2X7R expression in atrial cardiomyocytes of caveolin-1 deficient mice. *Histochem Cell Biol* **134**, 31–38 (2010).
40. Musa, H. *et al.* P2 purinergic receptor mRNA in rat and human sinoatrial node and other heart regions. *Naunyn Schmiedeberg Arch Pharmacol* **379**, 541–549 (2009).
41. Pelleg, A. & Belhassen, B. The Mechanism of the Negative Chronotropic and Dromotropic Actions of Adenosine 5'-triphosphate in the Heart: An Update. *J Cardiovasc Pharmacol* **56**, 106–109 (2010).
42. Hanna, E. B. & Glancy, D. L. ST-segment depression and T-wave inversion: classification, differential diagnosis, and caveats. *Cleve Clin J Med* **78**, 404–414 (2011).
43. Deten, A. *et al.* Norepinephrine-induced acute heart failure in transgenic mice overexpressing erythropoietin. *Cardiovasc Res* **61**, 105–114 (2004).
44. Chen, P. *et al.* Susceptibility to autoimmune myocarditis is associated with intrinsic differences in CD4+ T cells. *Clin Exp Immunol* **169**, 79–88 (2012).
45. Schenk, U. *et al.* ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. *Sci Signal* **4**, ra12 (2011).
46. Bonelli, M. *et al.* CD4 CD25– Foxp3 T cells: a marker for lupus nephritis? *Arthritis Res Ther* **2**, 1–11 (2014).
47. Yang, H. *et al.* Are CD4+ CD25–Foxp3+ cells in untreated new-onset lupus patients regulatory T cells. *Arthritis Res Ther* **11**, R153 (2009).
48. Zelenay, S. *et al.* Foxp3+ CD25–CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. *Proc Natl Acad Sci USA* **102**, 4091–4096 (2005).
49. Zóka, A. *et al.* Extension of the CD4+ Foxp3+ CD25(low) regulatory T-cell subpopulation in type 1 diabetes mellitus. *Autoimmunity*, 1–9 (2014).
50. Boari, J. T. *et al.* IL-17RA signaling reduces inflammation and mortality during *Trypanosoma cruzi* infection by recruiting suppressive IL-10-producing neutrophils. *PLoS Pathog* **8**, e1002658 (2012).
51. Chung, Y. *et al.* Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. *Immunity* **30**, 576–587 (2009).
52. Sutton, C., Brereton, C., Keogh, B., Mills, K. H. & Lavelle, E. C. A crucial role for interleukin IL-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. *J Exp Med* **203**, 1685–1691 (2006).
53. Rosas-Jorquera, C. E. *et al.* Challenge of Chronically Infected Mice with Homologous *Trypanosoma cruzi* Parasites Enhances the Immune Response but Does Not Modify Cardiopathy: Implications for the Design of a Therapeutic Vaccine. *Clin Vaccine Immunol* **20**, 248–254 (2013).
54. Cosper, P. F., Harvey, P. A. & Leinwand, L. A. Interferon- γ causes cardiac myocyte atrophy via selective degradation of myosin heavy chain in a model of chronic myocarditis. *Am J Pathol* **181**, 2038–2046 (2012).
55. Savvatis, K. *et al.* Interleukin-23 deficiency leads to impaired wound healing and adverse prognosis after myocardial infarction. *Circ Heart Fail* **7**, 161–171 (2014).
56. Torzewski, M. *et al.* Chronic inflammatory cardiomyopathy of interferon γ -overexpressing transgenic mice Is mediated by tumor necrosis factor- α . *Am J Pathol* **180**, 73–81 (2012).
57. Eriksson, U. *et al.* Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. *Nat Med* **9**, 1484–1490 (2003).
58. Le Feuvre, R. A., Brough, D., Iwakura, Y., Takeda, K. & Rothwell, N. J. Priming of macrophages with lipopolysaccharide potentiates P2X7-mediated cell death via a caspase-1-dependent mechanism, independently of cytokine production. *J Biol Chem* **277**, 3210–3218 (2002).

Acknowledgements

Sources of funding for this work were from the Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq/Doenças Negligenciadas, Fundação de Amparo a Pesquisa do Rio de Janeiro – FAPERJ/Doenças Negligenciadas and Instituto Nacional para Pesquisa Translacional em Saúde e

Ambiente na Região Amazônica - INPETAM, Conselho Nacional de Desenvolvimento Científico e Tecnológico/MCT. We thank Mrs Thayane Laranja dos Anjos for conducting some ergometric adaptation protocols and Mrs Ana Paula Masson for help in immunization procedures.

Author Contributions

Author contributions: C.G.M., P.M.P. and E.K. provided conception and design of research; C.G.M., D.Z.M., M.G.S., I.T.B. K.C.R. and M.B. performed experiments; C.G.M., D.Z.M., M.G.S., B.L.D., M.B., P.M.P. and E.K. analyzed data; C.G.M., P.M.P. and E.K. interpreted results of experiments; C.G.M. and K.C.R. prepared figures; C.G.M. and E.K. drafted manuscript; C.G.M., D.Z.M., M.G.S., M.B., P.M.P. and E.K. edited and revised manuscript; C.G.M., D.Z.M., M.G.S., I.T.K., C.L.S., B.L.D., M.B., P.M.P. and E.K. approved final version of manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Martinez, C. G. *et al.* P2×7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M₂ receptors: autoantibody levels, heart functionality and cytokine expression. *Sci. Rep.* 5, 16940; doi: 10.1038/srep16940 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>